Item 2.02 Results of Operations and Financial Condition.
On
The information in this Item 2.02, and Exhibit 99.1 attached hereto, is being
furnished and shall not be deemed "filed" for the purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject to the
liabilities of that Section. The information in this Item 2.02, and Exhibit 99.1
attached hereto, shall not be incorporated by reference into any registration
statement or other document filed with the
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits Exhibit No. Description 99.1 Press release ofTravere Therapeutics, Inc. datedJanuary 9, 2023 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
--------------------------------------------------------------------------------
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
TRAVERE THERAPEUTICS, INC. Dated: January 9, 2023 By: /s/ Elizabeth E. Reed Name: Elizabeth E. Reed Title: Senior Vice President, General Counsel and Secretary
© Edgar Online, source